((自动化翻译由路透提供,请见免责声明 ))
路透9月26日 - 美国食品和药物管理局周四提醒患者和医疗保健专业人员注意辉瑞公司 的镰状细胞病治疗药物Oxbryta的撤出。
辉瑞公司周三晚些时候说, (link),由于该药有可能引起一种痛苦的并发症和死亡,它将从所有市场上撤下该药。
美国食品和药物管理局说,它正在对该药的上市后临床数据进行安全性审查,还将审查真实世界的登记研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.